Pipeline

Orca-T

Orca-T is our lead investigational allogeneic T-cell immunotherapy designed to treat hematological malignancies like acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myelodysplastic syndrome (MDS). Orca-T is being tested under our Precision-T study, a pivotal, randomized Phase 3 clinical study comparing Orca-T to the current standard of care, a conventional allogeneic or autologous graft (allograft).

Orca-Q

Orca-Q is our next generation investigational allogeneic T-cell immunotherapy candidate. Orca-Q is designed to deliver therapeutic benefits without the need for a fully matched donor.

Our publications

Orca Bio continues to build important clinical evidence in support of its pipeline.

View our data publications

Review our policy on

Expanded Access for Investigational Medicines

Learn More
NEXT: For Patients and Their Families